产品描述
RPMI 1640 培养基以研发地点罗斯韦尔公园纪念研究所(Roswell Park Memorial Institute. RPMI)命名,1640为培养基代号。它是McCoy’s 5A培养基的改进型,使用碳酸氢盐缓冲系统。RPMI 1640培养基最初开发用于人白血病细胞的悬浮或单层培养,后来被发现也适用于多种哺乳动物细胞,包括HeLa、Jurkat、MCF-7、PC-12、PBMC、星形胶质细胞和癌细胞,尤其适用于悬浮细胞的培养,是使用最为广泛的培养基之一。
RPMI 1640培养基与其它培养基的区别在于含有还原型谷胱甘肽和高浓度的维生素。RPMI 1640培养基含有EMEM和DMEM中没有的生物素、维生素B12和对氨基苯甲酸,以及高浓度的氯化胆碱和肌醇。
我司可提供不同配方的RPMI 1640系列培养基以供不同的细胞培养应用,详情请见不同RPMI 1640的配方表。
With含有 | Without不含 |
• Glucose葡萄糖 (2000mg/L) | • Sodium Pyruvate丙酮酸钠 |
• L-Glutamine L-谷氨酰胺(300mg/L) | • HEPES |
• Phenol Red 酚红(5mg/L) |
详细配方请参考说明书
-
A second-generation M1-polarized CAR macrophage with antitumor efficacy
Nature Immunology
IF:30.5
年份:2023
-
ADVANCED MATERIALS
IF:29.4
年份:2023
-
Discovery of Novel Anti-Resistance AR Antagonists Guided by Funnel Metadynamics Simulation
Advanced Science
IF:14.3
年份:2024
-
Advanced Science
IF:14.3
年份:2024
-
Cell Reports Medicine
IF:11.7
年份:2024
-
Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming
Journal of Experimental & Clinical Cancer Research
IF:11.161
年份:2019
-
Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
Cell Death & Disease
IF:9.68
年份:2022
-
FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis
JCI Insight.
IF:9.48
年份:2022
-
PUF60 promotes cell cycle and lung cancer progression by regulating alternative splicing of CDC25C
Cell Reports
IF:8.8
年份:2023
-
Biomaterials Research
IF:8.1
年份:2024
-
Frontiers in Immunology
IF:7.3
年份:2022
-
Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities
Acta Pharmacologica Sinica
IF:7.169
年份:2023
-
Crizotinib and its enantiomer suppress ferroptosis by decreasing PE-O-PUFA content
Cell Death Discovery
IF:6.1
年份:2024
-
Front Pharmacol
IF:5.988
年份:2023
-
Galangin Inhibits Gastric Cancer Growth Through Enhancing STAT3 Mediated ROS Production
Front. Pharmacol
IF:5.813
年份:2021
-
Molecular Medicine
IF:5.7
年份:2023
-
Blocking VCAM-1 Prevents Angiotensin II-Induced Hypertension and Vascular Remodeling in Mice
Frontiers in Pharmacology
IF:5.6
年份:2022
-
Molecules
IF:4.2
年份:2024
-
Identification of homer protein homolog 3 as a prognostic marker of colon adenocarcinoma
Heliyon
IF:3.4
年份:2024
-
Journal of Cancer
IF:3.3
年份:2024
-
BMC Immunology
IF:3
年份:2024
-
J Food Biochem
IF:1.849
年份:2020